/
GTBP
$0.44+$0.01 (+2.33%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$15.5M
36M shares
52-week range
$0.26 – $3.73
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
4.20%
Moderate
Price (6 mo)
Loading chart…
Change$-457.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $7.0K | $4.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$7.0K | −$4.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $9.1M | $1.7M | $485.0K | $9.6M | $8.8M | $6.5M | $5.8M | $3.5M |
| Operating income | −$250.1M | −$11.5M | −$6.8M | −$57.5M | −$21.3M | −$13.6M | −$14.4M | −$12.4M |
| EBITDA | −$250.1M | −$36.5M | −$25.0M | −$57.5M | −$21.0M | $6.0M | −$13.2M | −$28.2M |
| Net income | −$259.2M | −$38.6M | −$28.3M | −$58.0M | −$20.9M | −$7.6M | −$13.2M | −$28.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -87.70 | -11.42 | -6.45 | -2.06 | -0.66 | -5.64 | -6.94 | -6.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.34 | $-0.34–$-0.34 | 1 |
| 2027 | $68M | $-0.27 | $-0.27–$-0.27 | 1 |
| 2028 | $0 | $-0.23 | $-0.23–$-0.23 | 1 |
| 2029 | $20M | $0.05 | $0.05–$0.05 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.11
Price
$0.44
Implied upside
+152%
Peer comparison
GT Biopharma Inc. Common Stock
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
www.gtbiopharma.com- Employees
- 1
- IPO / List date
- Feb 11, 2021
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds GTBP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 26,300 | $94.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-05 | 1-for-30reverse |
| 2021-02-11 | 1-for-17reverse |
Recent trades on TradeandTell
No one on the platform has traded GTBP yet.
